CNX-012-570, a direct AMPK activator provides strong glycemic and lipid control along with significant reduction in body weight; studies from both diet-induced obese mice and db/db mice models

Cardiovascular Diabetology

Volumn 13, Issue 1, 2014, Pages

  Anil, Tharappel M ^a   Harish, Chandrashekaran ^a   Lakshmi, Mudigere N ^a   Harsha, KrishnaReddy ^a   Onkaramurthy, Mallappa ^a   Sathish Kumar, Venkatesh ^a   Shree, Nitya ^a   Geetha, Venkatachalaiah ^a   Balamurali, Gundalmandikal V ^a   Gopala, Aralakuppe S ^a   Madhusudhan Reddy, Bobbili ^a   Govind, Madabosse K ^a   Anup, Mammen O ^a   Moolemath, Yoganand ^a   Venkataranganna, Marikunte V ^a   Jagannath, Madanahalli R ^a   Somesh, Baggavalli P ^a  

^a Connexios Life Sciences Pvt Ltd ^*  (India)

Author keywords

AMPK; Cholesterol and body weight; CNX 012 570; Glucose; Insulin sensitivity; Triglycerides

Indexed keywords

AMP-ACTIVATED PROTEIN KINASES; ANIMALS; BLOOD GLUCOSE; BODY WEIGHT; CHOLESTEROL; DIET, HIGH-FAT; ENZYME ACTIVATION; GLYCEMIC INDEX; HEP G2 CELLS; HUMANS; HYPOGLYCEMIC AGENTS; HYPOLIPIDEMIC AGENTS; MALE; MICE; MICE, INBRED C57BL; MICE, OBESE; OBESITY; TRIGLYCERIDES;

EID: 84892763310     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/1475-2840-13-27     Document Type: Article

References (45)

1. Steinberg GR, Kemp BE. AMPK in health and disease. Physiol Rev 2009, 89(3):1025-1078. 10.1152/physrev.00011.2008, 19584320.
2. Jiang S, Park DW, Stigler WS, Creighton J, Ravi S, Darley-Usmar V, Zmijewski JW. Mitochondria and AMP-activated protein kinase-dependent mechanism of efferocytosis. J Biol Chem 2013, 288(36):26013-26026. 10.1074/jbc.M113.489468, 23897815.
3. Marley AE, Sullivan JE, Carling D, Abbott WM, Smith GJ, Taylor IW, Carey F, Beri RK. Biochemical characterization and deletion analysis of recombinant human protein phosphatase 2C alpha. Biochem J 1996, 320(Pt 3):801-806. 1218000, 9003365.
4. Gimeno-Alcañiz JV, Sanz P. Glucose and type 2A protein phosphatase regulate the interaction between catalytic and regulatory subunits of AMP-activated protein kinase. J Mol Biol 2003, 333(1):201-209. 10.1016/j.jmb.2003.08.022, 14516753.
5. Voss M, Paterson J, Kelsall IR, Martín-Granados C, Hastie CJ, Peggie MW, Cohen PT. Ppm1E is an in cellulo AMP-activated protein kinase phosphatase. Cell Signal 2011, 23(1):114-124. 10.1016/j.cellsig.2010.08.010, 20801214.
6. Kodiha M, Ho-Wo-Cheong D, Stochaj U. Pharmacological AMP-kinase activators have compartment-specific effects on cell physiology. Am J Physiol Cell Physiol 2011, 301(6):C1307-C1315. 10.1152/ajpcell.00309.2011, 21918180.
7. McGee SL, Howlett KF, Starkie RL, Cameron-Smith D, Kemp BE, Hargreaves M. Exercise increases nuclear AMPK alpha2 in human skeletal muscle. Diabetes 2003, 52:926-928. 10.2337/diabetes.52.4.926, 12663462.
8. Salt I, Celler JW, Hawley SA, Prescott A, Woods A, Carling D, Hardie DG. AMP-activated protein kinase: greater AMP dependence, and preferential nuclear localization, of complexes containing the a2 isoform. Biochem J 1998, 334(Pt 1):177-187. 1219677, 9693118.
9. Ju TC, Chen HM, Lin JT, Chang CP, Chang WC, Kang JJ, Sun CP, Tao MH, Tu PH, Chang C, Dickson DW, Chern Y. Nuclear translocation of AMPK-alpha1 potentiates striatal neurodegeneration in Huntington's disease. J Cell Biol 2011, 194(2):209-227. 10.1083/jcb.201105010, 3144412, 21768291.
10. Kazgan N, Williams T, Forsberg LJ, Brenman JE. Identification of a nuclear export signal in the catalytic subunit of AMP-activated protein kinase. Mol Biol Cell 2010, 21(19):3433-3442. 10.1091/mbc.E10-04-0347, 2947478, 20685962.
11. Ruderman NB, Xu XJ, Lauren N, Cacicedo JM, Saha AK, Fan L, Yasuo I. AMPK and SIRT1: a long-standing partnership?. Am J Physiol Endocrinol Metab 2010, 298(4):E751-E760. 10.1152/ajpendo.00745.2009, 2853213, 20103737.
12. Viollet B, Andreelli F, Jørgensen SB, Perrin C, Geloen A, Flamez D, Mu J, Lenzner C, Baud O, Bennoun M, Gomas E, Nicolas G, Wojtaszewski JF, Kahn A, Carling D, Schuit FC, Birnbaum MJ, Richter EA, Burcelin R, Vaulont S. The AMP-activated protein kinase alpha2 catalytic subunit controls whole-body insulin sensitivity. J Clin Invest 2003, 111(1):91-98. 151837, 12511592.
13. Viollet B, Andreelli F, Jørgensen SB, Perrin C, Flamez D, Mu J, Wojtaszewski JF, Schuit FC, Birnbaum M, Richter E, Burcelin R, Vaulont S. Physiological role of AMP-activated protein kinase (AMPK): insights from knockout mouse models. Biochem Soc Trans 2003, 31(Pt 1):216-219.
14. Reznick RM, Zong H, Li J, Morino K, Moore IK, Yu HJ, Liu ZX, Dong J, Mustard KJ, Hawley SA, Befroy D, Pypaert M, Hardie DG, Young LH, Shulman GI. Aging-associated reductions in AMP-activated protein kinase activity and mitochondrial biogenesis. Cell Metab 2007, 5(2):151-156. 10.1016/j.cmet.2007.01.008, 1885964, 17276357.
15. Hong YH, Varanasi US, Yang W, Leff T. AMP-activated protein kinase regulates HNF4alpha transcriptional activity by inhibiting dimer formation and decreasing protein stability. J Biol Chem 2003, 278(30):27495-27501. 10.1074/jbc.M304112200, 12740371.
16. Ahmadian M, Abbott MJ, Tang T, Hudak CS, Kim Y, Bruss M, Hellerstein MK, Lee HY, Samuel VT, Shulman GI, Wang Y, Duncan RE, Kang C, Sul HS. Desnutrin/ATGL is regulated by AMPK and is required for a brown adipose phenotype. Cell Metab 2011, 13(6):739-748. 10.1016/j.cmet.2011.05.002, 3148136, 21641555.
17. Minokoshi Y, Kim YB, Peroni OD, Fryer LG, Müller C, Carling D, Kahn BB. Leptin stimulates fatty-acid oxidation by activating AMP-activated protein kinase. Nature 2002, 415(6869):339-343. 10.1038/415339a, 11797013.
18. Yamauchi T, Kamon J, Minokoshi Y, Ito Y, Waki H, Uchida S, Yamashita S, Noda M, Kita S, Ueki K, Eto K, Akanuma Y, Froguel P, Foufelle F, Ferre P, Carling D, Kimura S, Nagai R, Kahn BB, Kadowaki T. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 2002, 8(11):1288-1295. 10.1038/nm788, 12368907.
19. Salt IP, Palmer TM. Exploiting the anti-inflammatory effects of AMP-activated protein kinase activation. Expert Opin Investig Drugs 2012, 21(8):1155-1167. 10.1517/13543784.2012.696609, 22694351.
20. Bijland S, Mancini SJ, Salt IP. Role of AMP-activated protein kinase in adipose tissue metabolism and inflammation. Clin Sci (Lond) 2013, 124(8):491-507. 10.1042/CS20120536, 23298225.
21. Pinkosky SL, Filippov S, Srivastava RA, Hanselman JC, Bradshaw CD, Hurley TR, Cramer CT, Spahr MA, Brant AF, Houghton JL, Baker C, Naples M, Adeli K, Newton RS. AMP-activated protein kinase and ATP-citrate lyase are two distinct molecular targets for ETC-1002, a novel small molecule regulator of lipid and carbohydrate metabolism. J Lipid Res 2013, 54(1):134-151. 10.1194/jlr.M030528, 3520520, 23118444.
22. Cool B, Zinker B, Chiou W, Kifle L, Cao N, Perham M, Dickinson R, Adler A, Gagne G, Iyengar R, Zhao G, Marsh K, Kym P, Jung P, Camp HS, Frevert E. Identification and characterization of a small molecule AMPK activator that treats key components of type 2 diabetes and the metabolic syndrome. Cell Metab 2006, 3(6):403-416. 10.1016/j.cmet.2006.05.005, 16753576.
23. Kilkenny C, Browne WJ, Cuthill IC, Emerson M, Altman DG. Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research. PLoS Biol 2010, 8(6):e1000412. 10.1371/journal.pbio.1000412, 2893951, 20613859.
24. Corton JM, Gillespie JG, Hawley SA, Hardie DG. 5-aminoimidazole-4-carboxamide ribonucleoside. A specific method for activating AMP-activated protein kinase in intact cells?. Eur J Biochem 1995, 229(2):558-565. 10.1111/j.1432-1033.1995.tb20498.x, 7744080.
25. Hawley SA, Fullerton MD, Ross FA, Schertzer JD, Chevtzoff C, Walker KJ, Peggie MW, Zibrova D, Green KA, Mustard KJ, Kemp BE, Sakamoto K, Steinberg GR, Hardie DG. The ancient drug salicylate directly activates AMP-activated protein kinase. Science 2012, 336(6083):918-922. 10.1126/science.1215327, 3399766, 22517326.
26. Göransson O, McBride A, Hawley SA, Ross FA, Shpiro N, Foretz M, Viollet B, Hardie DG, Sakamoto K. Mechanism of action of A-769662, a valuable tool for activation of AMP-activated protein kinase. J Biol Chem 2007, 282(45):32549-32560. 10.1074/jbc.M706536200, 2156105, 17855357.
27. Stephenne X, Foretz M, Taleux N, van der Zon GC, Sokal E, Hue L, Viollet B, Guigas B. Metformin activates AMP-activated protein kinase in primary human hepatocytes by decreasing cellular energy status. Diabetologia 2011, 54(12):3101-3110. 10.1007/s00125-011-2311-5, 3210354, 21947382.
28. Vincent MF, Marangos PJ, Gruber HE, Van den Berghe G. Inhibition by AICA riboside of gluconeogenesis in isolated rat hepatocytes. Diabetes 1991, 40(10):1259-6. 10.2337/diab.40.10.1259, 1657665.
29. Shiota A, Shimabukuro M, Fukuda D, Soeki T, Sato H, Uematsu E, Hirata Y, Kurobe H, Maeda N, Sakaue H, Masuzaki H, Shimomura I, Sata M. Telmisartan ameliorates insulin sensitivity by activating the AMPK/SIRT1 pathway in skeletal muscle of obese db/db mice. Cardiovasc Diabetol 2012, 11:139. 10.1186/1475-2840-11-139, 3527353, 23137106.
30. Ueno M, Carvalheira JB, Tambascia RC, Bezerra RM, Amaral ME, Carneiro EM, Folli F, Franchini KG, Saad MJ. Regulation of insulin signalling by hyperinsulinaemia: role of IRS-1/2 serine phosphorylation and the mTOR/p70 S6K pathway. Diabetologia 2005, 48(3):506-518. 10.1007/s00125-004-1662-6, 15692808.
31. Oyadomari S, Harding HP, Zhang Y, Oyadomari M, Ron D. Dephosphorylation of translation initiation factor 2alpha enhances glucose tolerance and attenuates hepatosteatosis in mice. Cell Metab 2008, 7(6):520-532. 10.1016/j.cmet.2008.04.011, 2474721, 18522833.
32. Li Y, Xu S, Mihaylova MM, Zheng B, Hou X, Jiang B, Park O, Luo Z, Lefai E, Shyy JY, Gao B, Wierzbicki M, Verbeuren TJ, Shaw RJ, Cohen RA, Zang M. AMPK phosphorylates and inhibits SREBP activity to attenuate hepatic steatosis and atherosclerosis in diet-induced insulin-resistant mice. Cell Metab 2011, 13(4):376-388. 10.1016/j.cmet.2011.03.009, 3086578, 21459323.
33. Henin N, Vincent MF, Gruber HE, Van den Berghe G. Inhibition of fatty acid and cholesterol synthesis by stimulation of AMP-activated protein kinase. FASEB J 1995, 9(7):541-546.
34. Carling D, Clarke PR, Zammit VA, Hardie DG. Purification and characterization of the AMP-activated protein kinase. Copurification of acetyl-CoA carboxylase kinase and 3-hydroxy-3-methylglutaryl-CoA reductase kinase activities. Eur J Biochem 1989, 186(1-2):129-136. 10.1111/j.1432-1033.1989.tb15186.x, 2598924.
35. Abdelmalek MF, Diehl AM. Nonalcoholic fatty liver disease as a complication of insulin resistance. Med Clin North Am 2007, 91(6):1125-1149. 10.1016/j.mcna.2007.06.001, 17964913.
36. Shargorodsky M, Omelchenko E, Matas Z, Boaz M, Gavish D. Relation between augmentation index and adiponectin during one-year metformin treatment for nonalcoholic steatohepatosis: effects beyond glucose lowering?. Cardiovasc Diabetol 2012, 11:61. 10.1186/1475-2840-11-61, 3471007, 22676459.
37. Shimomura I, Bashmakov Y, Horton JD. Increased levels of nuclear SREBP-1c associated with fatty livers in two mouse models of diabetes mellitus. J Biol Chem 1999, 274(42):30028-30032. 10.1074/jbc.274.42.30028, 10514488.
38. Mandrekar P, Ambade A, Lim A, Szabo G, Catalano D. An essential role for monocyte chemoattractant protein-1 in alcoholic liver injury: regulation of proinflammatory cytokines and hepatic steatosis in mice. Hepatology 2011, 54(6):2185-2197. 10.1002/hep.24599, 3342822, 21826694.
39. Goodpaster BH, Katsiaras A, Kelley DE. Enhanced fat oxidation through physical activity is associated with improvements in insulin sensitivity in obesity. Diabetes 2003, 52(9):2191-2197. 10.2337/diabetes.52.9.2191, 12941756.
40. Goodpaster BH, Kelley DE, Wing RR, Meier A, Thaete FL. Effects of weight loss on regional fat distribution and insulin sensitivity in obesity. Diabetes 1999, 48(4):839-847. 10.2337/diabetes.48.4.839, 10102702.
41. Vila-Bedmar R, Lorenzo M, Fernández-Veledo S. Adenosine 5′-monophosphate-activated protein kinase-mammalian target of rapamycin cross talk regulates brown adipocyte differentiation. Endocrinology 2010, 151(3):980-992. 10.1210/en.2009-0810, 20133456.
42. Lemkes BA, Nieuwdorp M, Hoekstra JB, Holleman F. The glycocalyx and cardiovascular disease in diabetes: should we judge the endothelium by its cover?. Diabetes Technol Ther 2012, 14(Suppl 1):S3-S10.
43. Eskens BJ, Zuurbier CJ, Van Haare J, Vink H, Van Teeffelen JW. Effects of two weeks of metformin treatment on whole-body glycocalyx barrier properties in db/db mice. Cardiovasc Diabetol 2013, 12:175. 10.1186/1475-2840-12-175, 3866460, 24308370.
44. He C, Zhu H, Li H, Zou MH, Xie Z. Dissociation of Bcl-2-Beclin1 complex by activated AMPK enhances cardiac autophagy and protects against cardiomyocyte apoptosis in diabetes. Diabetes 2013, 62(4):1270-1281. 10.2337/db12-0533, 23223177.
45. Aragno M, Mastrocola R, Ghé C, Arnoletti E, Bassino E, Alloatti G, Muccioli G. Obestatin induced recovery of myocardial dysfunction in type 1 diabetic rats: underlying mechanisms. Cardiovasc Diabetol 2012, 11:129. 10.1186/1475-2840-11-129, 3537569, 23066908.